Tenaya Therapeutics, Inc. 8-K

What Happened Tenaya Therapeutics, Inc. filed an 8-K on January 2, 2026 disclosing that director David Goeddel submitted his resignation from the company’s board of directors and from all board committees. The resignation was submitted on December 31, 2025 and will be effective January 26, 2026. The company said the resignation is voluntary and due to Dr. Goeddel’s retirement, and is not the result of any disagreement with the company.

Key Details

• Filing: Form 8-K filed January 2, 2026 (Item 5.02).
• Resignation submitted: December 31, 2025; effective date: January 26, 2026.
• Scope: Resignation from the Board and all Board committees.
• Reason: Retirement; company states no disagreement with operations, policies, or practices.

Why It Matters This is a change in corporate governance — one board seat and associated committee memberships will be vacated as of January 26, 2026. For investors, such departures can affect board composition and oversight; the company may disclose a replacement or committee reassignments in a future filing. The 8-K indicates the departure is voluntary and not due to any dispute with management, which suggests no immediate operational concerns disclosed in this filing.